ArticleJournal of medical imaging and radiation oncology2025
Surveillance After Treatment of Adenoid Cystic Carcinoma of the Head and Neck: Review of Institutional Outcomes and Proposed Surveillance Imaging Protocol.
Article in Journal of medical imaging and radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- NI-RADS in posttreatment head and neck cancer surveillance: a framework for standardized imaging with clinical impact.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong term survival for adenoid cystic carcinoma (ACC) arising from the head and neck declines for many decades after initial treatment due to late disease relapse. Follow up and surveillance imaging practices vary due to limited evidence as well as a lack of international guidelines (until 2021).
methodsA retrospective cohort study was conducted for patients treated curatively for ACC between 2007 and 2024 at a single institution. Clinicopathologic information, treatment details, patterns of follow-up (including radiologic investigations) and oncological outcomes are reported.
results51 patients comprised the study cohort. Median age was 50 years; 96% of patients underwent surgery and adjuvant radiation therapy. Median follow-up was 7.65 years. 5-year overall survival (OS) and disease-free survival (DFS) were 88% and 73% respectively. 18% and 61% of patients underwent surveillance imaging within 3- and 12-months of treatment completion respectively. 80% of first recurrences were detected on surveillance imaging. Half the episodes of first disease recurrence occurred within 5 years of initial treatment, a further 25% within 10 years and the remaining 25% occurred > 10 years post treatment.
conclusionThis cohort of patients curatively treated for ACC at a single institution highlights the propensity for late distant relapse as well as heterogeneity of surveillance imaging. A local institutional protocol is proposed based upon the 2021 ASCO guidelines to standardise clinical and radiologic follow-up for this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.